血漿分画市場 : 2028年までの世界予測

Report Overview

The global plasma fractionation market size is projected to reach USD 40.4 billion by 2028 from USD 29.0 billion in 2023, at a CAGR of 6.9% during the forecast period. Expanding the number of plasma collection centers allows market players to collect a larger volume of plasma from donors. This increased supply of raw materials becomes the foundation for producing a greater quantity of plasma-derived products, meeting the growing demand in the market. For instance, in December 2022, CSL Behring (Australia) announced the opening of a USD 900 million Plasma Fractionation Facility in Victoria, Australia. The new state-of-the-art facility can process up to 9.2 million plasma equivalent liters per annum.

“The hospitals and clinics segment is expected to dominate the market during the forecast period.”

Based on end user, the plasma fractionation market is segmented into research laboratories, hospitals and clinics, and academic institutes. In 2022, the clinics and hospitals segment accounted for the largest share of the global plasma fractionation market. The growing number of hospitals and clinics in emerging and developed economies, as well as the improvement in healthcare infrastructure, are attributed to this segment’s major share in the market. Leading companies in this market are collaborating with hospitals to conduct clinical trials and promote awareness about the use of plasma products in the treatment of rare diseases. The demand for plasma products for the treatment of many rare and life-threatening disorders like hemophilia, PID, and COVID-19 is anticipated to increase as a result of such initiatives by companies and hospitals.

“The pulmonology application segment will witness the highest growth in the plasma fractionation market.”

Based on application, the plasma fractionation market is segmented into hematology, critical care, pulmonology neurology, immunology, , hemato-oncology, rheumatology, and other applications. In 2022, the pulmonology segment is expected to register the highest CAGR during the forecast period. The two major plasma products used in the treatment of various respiratory disorders are immunoglobulins and protease inhibitors. The main functions of immunoglobulins are the prevention and treatment of upper and lower respiratory tract infections. The market for pulmonology applications has grown significantly in recent years due to the significant growth in the usage of protease inhibitors, such as alpha-1-antitrypsin.


“North America will dominate the market during the forecast period.”

Based on region, the plasma fractionation market is further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2022, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. North America’s dominance in the global market is due to the fact that top players are continuously engaged in adopting various organic and inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market position. Major players in this industry in the area use the expansion of fractionation plants with cutting-edge technologies as a key growth strategy. The top competitors also focus on acquiring plasma collecting facilities to increase their market share in North America.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side – 70% and Demand Type – 30%
• By Designation: Managers – 45%, Directors – 30%, and Executives – 25%
• By Region: North America -25%, Europe -25%, Asia-Pacific -40%, Latin America-5%, Middle East -2.5% & Africa- 2.5%

List of Companies Profiled in the Report
• CSL (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Kedrion S.P.A (Italy)
• LFB (France)
• ADMA Biologics (US)
• Sanquin (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)
• Hualan Bioengineering Co., Ltd. (China)
• Japan Blood Products Organization (Japan)
• Emergent BioSolutions (US)
• Shanghai Raas Blood Products Co., Ltd. (China)
• Intas Pharmaceuticals Ltd. (India)
• Bharat Serum Vaccines Limited (India)
• SK Plasma (Korea)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
• Kamada (Israel)
• Centurion Pharma (Istanbul)
• Prothya Biosolutions (Netherlands)
• PlasmaGen BioSciences Pvt. Ltd. (India)
• Virchow Biotech Private Limited (India)
• Fusion Healthcare (India)
• Hemarus Therapeutics Limited (India)

Research Coverage:
This report provides a detailed picture of the plasma fractionation market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.


The report provides insights on the following pointers:
• Analysis of key drivers (growing use of immunoglobulins in various therapeutic areas, strategic expansion of plasma collection centers/inventories by market players, growing prevalence of respiratory diseases and AATD), restraints (high costs and limited reimbursements for plasma products, market disruption caused by recombinant alternatives), opportunities (government strategies increasing regional self-sufficiency), and challenges (stringent government regulations for maintaining safety and quality of plasma products) influencing the growth of the plasma fractionation market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the plasma fractionation market.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various plasma fractionation facilities across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), among others in the plasma fractionation market.

Table of Contents

1 INTRODUCTION 50
1.1 STUDY OBJECTIVES 50
1.2 MARKET DEFINITION 50
1.2.1 INCLUSIONS AND EXCLUSIONS 50
1.3 MARKET SCOPE 51
FIGURE 1 PLASMA FRACTIONATION MARKET SEGMENTATION 51
1.4 YEARS CONSIDERED 52
1.5 CURRENCY CONSIDERED 52
1.6 RESEARCH LIMITATIONS 52
1.7 STAKEHOLDERS 53
1.8 SUMMARY OF CHANGES 53
1.8.1 RECESSION IMPACT: PLASMA FRACTIONATION MARKET 54
2 RESEARCH METHODOLOGY 55
2.1 RESEARCH DATA 55
FIGURE 2 RESEARCH DESIGN 55
2.1.1 SECONDARY DATA 56
2.1.2 PRIMARY DATA 56
FIGURE 3 PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES 57
2.2 MARKET SIZE ESTIMATION 58
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS, 2022 58
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 59
FIGURE 6 ILLUSTRATIVE EXAMPLE OF CSL: REVENUE SHARE ANALYSIS, 2022 59
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 60
FIGURE 7 MARKET GROWTH FACTORS VALIDATION FROM PRIMARY EXPERTS 60
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 61
2.3 GROWTH FORECAST 62
FIGURE 9 PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS, 2023–2028 62
FIGURE 10 PLASMA FRACTIONATION MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 64
FIGURE 11 DATA TRIANGULATION METHODOLOGY 64
2.5 STUDY ASSUMPTIONS 65
2.6 RISK ANALYSIS 65
2.7 RECESSION IMPACT ANALYSIS: PLASMA FRACTIONATION MARKET 65
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH) 66
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 66
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 66
3 EXECUTIVE SUMMARY 68
FIGURE 12 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 68
FIGURE 13 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 69
FIGURE 14 PLASMA FRACTIONATION MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 69
FIGURE 15 REGIONAL SNAPSHOT: PLASMA FRACTIONATION MARKET 70
4 PREMIUM INSIGHTS 71
4.1 PLASMA FRACTIONATION MARKET OVERVIEW 71
FIGURE 16 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS TO DRIVE MARKET 71
4.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT AND COUNTRY (2022) 72
FIGURE 17 IMMUNOGLOBULINS AND US DOMINATED NORTH AMERICAN PLASMA FRACTIONATION MARKET IN 2022 72
4.3 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 73
FIGURE 18 IMMUNOGLOBULINS SEGMENT TO DOMINATE PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD 73
4.4 PLASMA FRACTIONATION MARKET, BY END USER, 2022 73
FIGURE 19 HOSPITALS AND CLINICS SEGMENT COMMANDED LARGEST MARKET SHARE IN PLASMA FRACTIONATION MARKET IN 2022 73
4.5 PLASMA FRACTIONATION MARKET: REGIONAL GROWTH OPPORTUNITIES 74
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN PLASMA FRACTIONATION MARKET FROM 2023 TO 2028 74
5 MARKET OVERVIEW 75
5.1 INTRODUCTION 75
FIGURE 21 PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
5.2 MARKET DYNAMICS 76
TABLE 4 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS 76
5.2.1 DRIVERS 76
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas 76
TABLE 5 OFF-LABEL INDICATIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) 77
TABLE 6 ON-LABEL INDICATIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) 78
TABLE 7 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY COUNTRY/REGION (2020–2021) 79
TABLE 8 NUMBER OF PATIENTS TREATED FOR TOP 15 TARGET CONDITIONS IN UK 79
5.2.1.2 Strategic expansion of plasma collection centers/inventories by market players 80
5.2.1.3 Growing prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency 81
5.2.2 RESTRAINTS 81
5.2.2.1 High costs and limited reimbursements for plasma-derived products 81
5.2.2.2 Market disruption caused by recombinant alternatives 82
5.2.3 OPPORTUNITIES 82
5.2.3.1 Government strategies for increasing regional self-sufficiency in plasma fractionation 82
5.2.4 CHALLENGES 83
5.2.4.1 Stringent government regulations for maintaining safety and quality of plasma-derived products 83
5.3 PRICING ANALYSIS 84
TABLE 9 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY KEY PLAYER, 2022 (USD) 84
TABLE 10 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION, 2021 (USD) 84
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85
FIGURE 22 REVENUE SHIFT AND NEW POCKETS FOR PLASMA FRACTIONATION PRODUCT PROVIDERS 85
5.5 VALUE CHAIN ANALYSIS 85
FIGURE 23 PROCEDURE OF PLASMA FRACTIONATION 86
FIGURE 24 VALUE CHAIN ANALYSIS: PLASMA FRACTIONATION MARKET 87
5.6 SUPPLY CHAIN ANALYSIS 87
FIGURE 25 SUPPLY CHAIN ANALYSIS: PLASMA FRACTIONATION MARKET 88
5.7 ECOSYSTEM MARKET MAP 89
FIGURE 26 ECOSYSTEM MARKET MAP: PLASMA FRACTIONATION MARKET 89
TABLE 11 ROLE IN ECOSYSTEM (SUPPLY SIDE/DEMAND SIDE): PLASMA FRACTIONATION MARKET 90
5.8 PATENT ANALYSIS 92
FIGURE 27 PATENT APPLICATIONS FOR PLASMA FRACTIONATION MARKET, JANUARY 2013–JULY 2023 92
5.9 KEY CONFERENCES AND EVENTS IN 2023–2024 93
TABLE 12 PLASMA FRACTIONATION MARKET: LIST OF CONFERENCES AND EVENTS IN 2023–2024 93
5.10 REGULATORY ANALYSIS 93
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 17 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
5.10.1 REGULATORY SCENARIO IN DIFFERENT COUNTRIES/REGIONS 95
5.11 PORTER’S FIVE FORCES ANALYSIS 97
TABLE 18 PORTER’S FIVE FORCES ANALYSIS: PLASMA FRACTIONATION MARKET 97
5.11.1 THREAT OF NEW ENTRANTS 97
5.11.2 THREAT OF SUBSTITUTES 97
5.11.3 BARGAINING POWER OF BUYERS 98
5.11.4 BARGAINING POWER OF SUPPLIERS 98
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 98
5.12 TECHNOLOGY ANALYSIS 99
5.12.1 COHN’S COLD ETHANOL PLASMA FRACTIONATION 99
5.12.2 GEL FILTRATION PLASMA FRACTIONATION 99
5.12.3 HUMAN PLASMA FRACTIONATION BY POLYETHYLENE GLYCOL 99
5.12.4 PLASMA FRACTIONATION BY AMMONIUM SULFATE 99
5.12.5 PLASMA FRACTIONATION BY CENTRIFUGATION 100
5.12.6 DEPTH FILTRATION PLASMA FRACTIONATION 100
5.12.7 PLASMA FRACTIONATION BY CHROMATOGRAPHY 100
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 100
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PLASMA FRACTIONATION PRODUCTS 100
5.14 KEY BUYING CRITERIA, BY END USER 101
FIGURE 29 KEY BUYING CRITERIA OF END USERS IN PLASMA FRACTIONATION MARKET 101
5.15 PLASMA COLLECTION, BY VOLUME 101
5.15.1 US 101
5.15.2 CANADA 102
5.15.3 UK 102
5.15.4 JAPAN 102
5.15.5 INDIA 102
5.15.6 BRAZIL 103
5.16 PLASMA COLLECTION CENTERS 103
FIGURE 30 PLASMA COLLECTION CENTERS IN NORTH AMERICA, 2010–2021 103
TABLE 19 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021–2022 104
6 PLASMA FRACTIONATION MARKET, BY PRODUCT 105
6.1 INTRODUCTION 106
TABLE 20 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 106
6.2 IMMUNOGLOBULINS 106
TABLE 21 INTRAVENOUS IMMUNOGLOBULINS (IVIG) VS. SUBCUTANEOUS IMMUNOGLOBULINS (SCIG) THERAPY 107
TABLE 22 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 23 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 24 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 25 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 26 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 27 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 28 PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 110
6.2.1 IVIG 110
6.2.1.1 Intravenous immunoglobulins segment to dominate plasma fractionation immunoglobulins market during study period 110
TABLE 29 IVIG OFFERED BY KEY PLAYERS 111
TABLE 30 IVIG MARKET, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 31 IVIG MARKET, BY REGION, 2021–2028 (METRIC TONS) 113
TABLE 32 NORTH AMERICA: IVIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 33 NORTH AMERICA: IVIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 113
TABLE 34 EUROPE: IVIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 35 EUROPE: IVIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 114
TABLE 36 ASIA PACIFIC: IVIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 37 ASIA PACIFIC: IVIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 115
TABLE 38 LATIN AMERICA: IVIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 39 LATIN AMERICA: IVIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 116
TABLE 40 MIDDLE EAST & AFRICA: IVIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 41 MIDDLE EAST & AFRICA: IVIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 116
6.2.2 SCIG 117
6.2.2.1 Ease of self-administration and lower incidence of non-serious systemic adverse reactions to drive segment 117
TABLE 42 SCIG OFFERED BY KEY PLAYERS 117
TABLE 43 SCIG MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 44 SCIG MARKET, BY REGION, 2021–2028 (METRIC TONS) 118
TABLE 45 NORTH AMERICA: SCIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 46 NORTH AMERICA: SCIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 119
TABLE 47 EUROPE: SCIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 48 EUROPE: SCIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 119
TABLE 49 ASIA PACIFIC: SCIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 50 ASIA PACIFIC: SCIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 120
TABLE 51 LATIN AMERICA: SCIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 52 LATIN AMERICA: SCIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 121
TABLE 53 MIDDLE EAST & AFRICA: SCIG MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 54 MIDDLE EAST & AFRICA: SCIG MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 121
6.2.3 OTHER IMMUNOGLOBULINS 122
TABLE 55 OTHER IMMUNOGLOBULINS OFFERED BY KEY PLAYERS 122
TABLE 56 OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 57 OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2021–2028 (METRIC TONS) 124
TABLE 58 NORTH AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 59 NORTH AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 125
TABLE 60 EUROPE: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 61 EUROPE: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 126
TABLE 62 ASIA PACIFIC: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 63 ASIA PACIFIC: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 127
TABLE 64 LATIN AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 65 LATIN AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 127
TABLE 66 MIDDLE EAST & AFRICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 67 MIDDLE EAST & AFRICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 128
6.3 COAGULATION FACTOR CONCENTRATES 128
TABLE 68 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 69 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 70 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 71 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 72 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 73 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 74 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 131
6.3.1 FACTOR VIII 132
6.3.1.1 Factor VIII held largest share of coagulation factor concentrates market in 2022 132
TABLE 75 FACTOR VIII OFFERED BY KEY PLAYERS 132
TABLE 76 FACTOR VIII MARKET, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 77 FACTOR VIII MARKET, BY REGION, 2021–2028 (MILLION IU) 133
TABLE 78 NORTH AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 79 NORTH AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 134
TABLE 80 EUROPE: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 81 EUROPE: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 134
TABLE 82 ASIA PACIFIC: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 83 ASIA PACIFIC: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 135
TABLE 84 LATIN AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 85 LATIN AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 136
TABLE 86 MIDDLE EAST & AFRICA: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 87 MIDDLE EAST & AFRICA: FACTOR VIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 136
6.3.2 FACTOR IX 137
6.3.2.1 Routine use of human plasma-derived factor IX concentrates in hemophilia treatment to drive segment 137
TABLE 88 FACTOR IX OFFERED BY KEY PLAYERS 137
TABLE 89 FACTOR IX MARKET, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 90 FACTOR IX MARKET, BY REGION, 2021–2028 (MILLION IU) 138
TABLE 91 NORTH AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 92 NORTH AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 139
TABLE 93 EUROPE: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 94 EUROPE: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 139
TABLE 95 ASIA PACIFIC: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 96 ASIA PACIFIC: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 140
TABLE 97 LATIN AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 98 LATIN AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 141
TABLE 99 MIDDLE EAST & AFRICA: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 100 MIDDLE EAST & AFRICA: FACTOR IX MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 141
6.3.3 VON WILLEBRAND FACTOR 142
6.3.3.1 Increasing prevalence and early diagnosis of hemophilia to drive segment 142
TABLE 101 VON WILLEBRAND FACTOR OFFERED BY KEY PLAYERS 142
TABLE 102 VON WILLEBRAND FACTOR MARKET, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 103 VON WILLEBRAND FACTOR MARKET, BY REGION, 2021–2028 (MILLION LITER) 143
TABLE 104 NORTH AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 105 NORTH AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 144
TABLE 106 EUROPE: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 107 EUROPE: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 144
TABLE 108 ASIA PACIFIC: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 109 ASIA PACIFIC: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 145
TABLE 110 LATIN AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 111 LATIN AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 146
TABLE 112 MIDDLE EAST & AFRICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 113 MIDDLE EAST & AFRICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 147
6.3.4 PROTHROMBIN COMPLEX CONCENTRATES 147
6.3.4.1 Advantages of prothrombin complex concentrate over fresh frozen plasma to drive segment 147
TABLE 114 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY PLAYERS 147
TABLE 115 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY REGION, 2021–2028 (USD MILLION) 148
TABLE 116 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY REGION, 2021–2028 (MILLION LITER) 148
TABLE 117 NORTH AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 118 NORTH AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 149
TABLE 119 EUROPE: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 120 EUROPE: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 149
TABLE 121 ASIA PACIFIC: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 122 ASIA PACIFIC: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 150
TABLE 123 LATIN AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 124 LATIN AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 151
TABLE 125 MIDDLE EAST & AFRICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 126 MIDDLE EAST & AFRICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 152
6.3.5 FIBRINOGEN CONCENTRATES 152
6.3.5.1 Better safety profile, greater accuracy, and higher speed of administration to drive segment 152
TABLE 127 FIBRINOGEN CONCENTRATES OFFERED BY KEY PLAYERS 152
TABLE 128 FIBRINOGEN CONCENTRATES MARKET, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 129 FIBRINOGEN CONCENTRATES MARKET, BY REGION, 2021–2028 (METRIC TONS) 153
TABLE 130 NORTH AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 131 NORTH AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 154
TABLE 132 EUROPE: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 133 EUROPE: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 154
TABLE 134 ASIA PACIFIC: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 135 ASIA PACIFIC: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 155
TABLE 136 LATIN AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 137 LATIN AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 156
TABLE 138 MIDDLE EAST & AFRICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 139 MIDDLE EAST & AFRICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (METRIC TONS) 157
6.3.6 FACTOR XIII 157
6.3.6.1 Applications in treating rare bleeding disorders and preventing surgical bleeding to drive segment 157
TABLE 140 FACTOR XIII OFFERED BY KEY PLAYERS 157
TABLE 141 FACTOR XIII MARKET, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 142 FACTOR XIII, BY REGION, 2021–2028 (MILLION IU) 158
TABLE 143 NORTH AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 144 NORTH AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 158
TABLE 145 EUROPE: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 146 EUROPE FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 159
TABLE 147 ASIA PACIFIC: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 148 ASIA PACIFIC: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 160
TABLE 149 LATIN AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 150 LATIN AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 161
TABLE 151 MIDDLE EAST & AFRICA: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 152 MIDDLE EAST & AFRICA: FACTOR XIII MARKET, BY COUNTRY, 2021–2028 (MILLION IU) 162
6.3.7 OTHER COAGULATION FACTOR CONCENTRATES 162
TABLE 153 OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, 2021–2028 (USD MILLION) 162
TABLE 154 NORTH AMERICA: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 155 EUROPE: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 156 ASIA PACIFIC: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 157 LATIN AMERICA: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 158 MIDDLE EAST & AFRICA: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
6.4 ALBUMIN 165
6.4.1 RISING DEMAND IN MAINTAINING ONCOTIC PRESSURE AND CONDUCTING MEDICAL TREATMENTS TO DRIVE MARKET 165
TABLE 159 ALBUMIN OFFERED BY KEY PLAYERS 166
TABLE 160 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 161 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2021–2028 (MILLION LITER) 167
TABLE 162 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 163 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (METRIC TONS) 168
TABLE 164 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 165 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (METRIC TONS) 168
TABLE 166 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 167 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (METRIC TONS) 169
TABLE 168 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 169 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (METRIC TONS) 170
TABLE 170 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 171 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021–2028 (METRIC TONS) 171
6.5 PROTEASE INHIBITORS 171
6.5.1 RISING PREVALENCE OF COPD AND OTHER RESPIRATORY DISEASES GLOBALLY TO DRIVE MARKET 171
TABLE 172 PROTEASE INHIBITORS OFFERED BY KEY PLAYERS 171
TABLE 173 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021–2028 (USD MILLION) 172
TABLE 174 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021–2028 (MILLION IU) 172
TABLE 175 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 176 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (MILLION IU) 173
TABLE 177 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 178 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (MILLION IU) 174
TABLE 179 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 180 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (MILLION IU) 175
TABLE 181 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 182 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (MILLION IU) 175
TABLE 183 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 184 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021–2028 (MILLION IU) 176
6.6 OTHER PLASMA PRODUCTS 176
TABLE 185 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 186 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 187 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 188 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 189 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 190 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 179
7 PLASMA FRACTIONATION MARKET, BY APPLICATION 180
7.1 INTRODUCTION 181
TABLE 191 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
7.2 NEUROLOGY 181
7.2.1 RISING PREVALENCE OF AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET 181
TABLE 192 DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR NEUROLOGICAL DISORDERS AND PROJECTED PERCENTAGE (2005 VS. 2015 VS. 2030) 182
TABLE 193 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN NEUROLOGY 183
TABLE 194 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 195 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 196 EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, 2021–2028 (USD MILLION) 184
TABLE 197 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 198 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 199 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 186
7.3 IMMUNOLOGY 186
7.3.1 ADVANCEMENTS IN GENETICS RESEARCH AND NOVEL THERAPEUTIC STRATEGIES TO DRIVE MARKET 186
TABLE 200 PHYSICIAN-REPORTED PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASES AMONG PATIENTS, BY REGION, 2013–2021 187
TABLE 201 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY 188
TABLE 202 DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASES 189
TABLE 203 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY 189
TABLE 204 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 190
TABLE 205 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 206 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, 2021–2028 (USD MILLION) 190
TABLE 207 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 208 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 209 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 192
7.4 HEMATOLOGY 192
7.4.1 GROWING NUMBER OF HEMOPHILIA PATIENTS TO DRIVE DEMAND FOR COAGULATION FACTORS 192
TABLE 210 NUMBER OF IDENTIFIED PATIENTS, BY INDICATION, 2021 192
FIGURE 31 DISTRIBUTION OF HEMOPHILIA PATIENTS, BY REGION, 2022 193
TABLE 211 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION, 2021–2028 (USD MILLION) 194
TABLE 212 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 213 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, 2021–2028 (USD MILLION) 194
TABLE 214 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 215 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 216 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 196
7.5 CRITICAL CARE 196
7.5.1 INCREASING OFF-LABEL USE OF ALBUMIN TO DRIVE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS 196
TABLE 217 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN CRITICAL CARE 197
TABLE 218 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION, 2021–2028 (USD MILLION) 197
TABLE 219 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 220 EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, 2021–2028 (USD MILLION) 198
TABLE 221 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 222 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 223 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021–2028 (USD MILLION) 200
7.6 PULMONOLOGY 200
7.6.1 RISING PREVALENCE OF ALPHA-1-ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE MARKET 200
TABLE 224 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN PULMONOLOGY 201
TABLE 225 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION, 2021–2028 (USD MILLION) 201
TABLE 226 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 227 EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, 2021–2028 (USD MILLION) 202
TABLE 228 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 229 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 230 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 203
7.7 HEMATO-ONCOLOGY 203
7.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE MARKET 203
TABLE 231 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN HEMATO-ONCOLOGY 204
TABLE 232 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 204
TABLE 233 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 234 EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, 2021–2028 (USD MILLION) 205
TABLE 235 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 236 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 237 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 206
7.8 RHEUMATOLOGY 206
7.8.1 INCREASING PREVALENCE OF RHEUMATIC ARTHRITIS IN DEVELOPED COUNTRIES TO DRIVE MARKET 206
TABLE 238 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION, 2021–2028 (USD MILLION) 207
TABLE 239 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 207
TABLE 240 EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, 2021–2028 (USD MILLION) 207
TABLE 241 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 208
TABLE 242 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 208
TABLE 243 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 209
7.9 OTHER APPLICATIONS 209
TABLE 244 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS 210
TABLE 245 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 210
TABLE 246 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 211
TABLE 247 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, 2021–2028 (USD MILLION) 211
TABLE 248 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 212
TABLE 249 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 212
TABLE 250 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 213
8 PLASMA FRACTIONATION MARKET, BY END USER 214
8.1 INTRODUCTION 215
TABLE 251 PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 215
8.2 HOSPITALS AND CLINICS 215
8.2.1 GROWING NUMBER OF SURGERIES AND INCREASING OFF-LABEL USE OF IMMUNOGLOBULINS TO DRIVE MARKET 215
TABLE 252 PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 216
TABLE 253 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 254 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 217
TABLE 255 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 217
TABLE 256 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, 2021–2028 (USD MILLION) 218
TABLE 257 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 218
8.3 CLINICAL RESEARCH LABORATORIES 218
8.3.1 INCREASING CLINICAL STUDIES ON NEW INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE MARKET 218
TABLE 258 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 219
TABLE 259 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 219
TABLE 260 EUROPE: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 220
TABLE 261 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 220
TABLE 262 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, 2021–2028 (USD MILLION) 221
TABLE 263 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021–2028

8.4 ACADEMIC INSTITUTES 221
8.4.1 GROWING STUDIES ON SAFETY AND EFFICACY OF PLASMA-DERIVED PRODUCTS TO DRIVE MARKET 221
TABLE 264 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 222
TABLE 265 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 222
TABLE 266 EUROPE: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 223
TABLE 267 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 223
TABLE 268 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, 2021–2028 (USD MILLION) 224
TABLE 269 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 224
9 PLASMA FRACTIONATION MARKET, BY REGION 225
9.1 INTRODUCTION 226
TABLE 270 PLASMA FRACTIONATION MARKET, BY REGION, 2021–2028 (USD MILLION) 226
9.2 NORTH AMERICA 227
FIGURE 32 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT 227
TABLE 271 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 228
TABLE 272 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 228
TABLE 273 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 274 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 275 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 229
TABLE 276 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 230
9.2.1 US 230
9.2.1.1 US to dominate market for plasma fractionation products during forecast period 230
TABLE 277 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 231
TABLE 278 US: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 279 US: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 280 US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 232
TABLE 281 US: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 233
9.2.2 CANADA 233
9.2.2.1 High per capita usage of immunoglobulins and increased number of blood-related diseases to drive market 233
TABLE 282 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 234
TABLE 283 CANADA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 284 CANADA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 285 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 235
TABLE 286 CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 236
9.3 EUROPE 236
TABLE 287 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 288 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 237
TABLE 289 EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 290 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 291 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 238
TABLE 292 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 239
9.3.1 GERMANY 239
9.3.1.1 Largest plasma fractionation capacity and highest number of plasma collection centers in Europe to drive market 239
TABLE 293 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 240
TABLE 294 GERMANY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 295 GERMANY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 296 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 241
TABLE 297 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 242
9.3.2 UK 242
9.3.2.1 Increased incidence of hemophilia and lift on ban of plasma donation to drive market 242
TABLE 298 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 243
TABLE 299 UK: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 300 UK: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 301 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 244
TABLE 302 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 245
9.3.3 FRANCE 245
9.3.3.1 High prevalence of bleeding disorders to drive market 245
TABLE 303 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2021 245
TABLE 304 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 246
TABLE 305 FRANCE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 306 FRANCE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 307 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 247
TABLE 308 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 248
9.3.4 ITALY 248
9.3.4.1 Growth in geriatric population to drive demand for plasma fractionation products 248
TABLE 309 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018, AND 2023) 249
TABLE 310 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 249
TABLE 311 ITALY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 312 ITALY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 313 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 250
TABLE 314 ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 251
9.3.5 SPAIN 251
9.3.5.1 Growing demand for plasma products for treatment of chronic diseases in geriatric population to drive market 251
TABLE 315 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 251
TABLE 316 SPAIN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 317 SPAIN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 318 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 253
TABLE 319 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 253
9.3.6 REST OF EUROPE 253
TABLE 320 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 254
TABLE 321 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 322 REST OF EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 323 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 255
TABLE 324 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 256
9.4 ASIA PACIFIC 256
FIGURE 33 ASIA PACIFIC: PLASMA FRACTIONATION MARKET SNAPSHOT 257
TABLE 325 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 258
TABLE 326 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 258
TABLE 327 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 328 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 329 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 330 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 260
9.4.1 CHINA 260
9.4.1.1 Rising incidence of chronic diseases and growing geriatric population to drive market 260
TABLE 331 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 261
TABLE 332 CHINA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 333 CHINA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 334 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 263
TABLE 335 CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 263
9.4.2 JAPAN 263
9.4.2.1 Rising prevalence of neurological disorders and hematological diseases to drive market 263
TABLE 336 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2018 (IN IU/TOTAL POPULATION) 264
TABLE 337 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2021 264
TABLE 338 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 265
TABLE 339 JAPAN: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 340 JAPAN: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 266
TABLE 341 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 266
TABLE 342 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 267
9.4.3 AUSTRALIA 267
9.4.3.1 Growing demand for plasma products and rising geriatric population to drive market 267
TABLE 343 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2008/09–2017/18 267
TABLE 344 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017–2018) 268
TABLE 345 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 268
TABLE 346 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 347 AUSTRALIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 348 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 269
TABLE 349 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 270
9.4.4 INDIA 270
9.4.4.1 Growing healthcare awareness, increasing availability of better diagnostic tools, and rising geriatric population to drive market 270
TABLE 350 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2021 271
TABLE 351 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 271
TABLE 352 INDIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 353 INDIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 354 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 273
TABLE 355 INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 273
9.4.5 VIETNAM 273
9.4.5.1 Increasing number of patients suffering from COPD, PID, and bleeding disorders to drive market 273
TABLE 356 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 274
TABLE 357 VIETNAM: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 358 VIETNAM: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 359 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 275
TABLE 360 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 276
9.4.6 INDONESIA 276
9.4.6.1 Rising number of government initiatives and growing geriatric population to boost market 276
TABLE 361 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 277
TABLE 362 INDONESIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 363 INDONESIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 364 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 278
TABLE 365 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 279
9.4.7 MALAYSIA 279
9.4.7.1 Increasing prevalence of bleeding disorders to drive market 279
TABLE 366 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 280
TABLE 367 MALAYSIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 280
TABLE 368 MALAYSIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 281
TABLE 369 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 281
TABLE 370 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 282
9.4.8 REST OF ASIA PACIFIC 282
TABLE 371 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 283
TABLE 372 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 283
TABLE 373 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 284
TABLE 374 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 284
TABLE 375 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 285
9.5 LATIN AMERICA 285
TABLE 376 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 285
TABLE 377 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 286
TABLE 378 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 286
TABLE 379 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 380 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 287
TABLE 381 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 288
9.5.1 BRAZIL 288
9.5.1.1 Growing incidence of immunodeficiency diseases and rising number of hemophilic patients to drive market 288
TABLE 382 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 288
TABLE 383 BRAZIL: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 289
TABLE 384 BRAZIL: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 289
TABLE 385 BRAZIL: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 290
TABLE 386 BRAZIL: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 290
9.5.2 REST OF LATIN AMERICA 290
TABLE 387 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 291
TABLE 388 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 291
TABLE 389 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 292
TABLE 390 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 292
TABLE 391 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 293
9.6 MIDDLE EAST & AFRICA 293
TABLE 392 HEMOPHILIA PATIENTS IN MIDDLE EAST & AFRICA, BY COUNTRY, 2012–2020 293
TABLE 393 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 294
TABLE 394 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 294
TABLE 395 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 295
TABLE 396 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 295
TABLE 397 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 296
TABLE 398 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 296
9.6.1 TURKEY 296
9.6.1.1 Turkey to dominate plasma fractionation market in Middle East & Africa during study period 296
TABLE 399 TURKEY: DEMOGRAPHIC INDICATORS 297
TABLE 400 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 297
TABLE 401 TURKEY: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 297
TABLE 402 TURKEY: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 298
TABLE 403 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 298
TABLE 404 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 299
9.6.2 SAUDI ARABIA 299
9.6.2.1 Developments in healthcare infrastructure to drive market 299
TABLE 405 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 300
TABLE 406 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 300
TABLE 407 SAUDI ARABIA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 301
TABLE 408 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 301
TABLE 409 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 302
9.6.3 EGYPT 302
9.6.3.1 Increasing research on plasma and plasma derivatives by government organizations to drive market 302
TABLE 410 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 303
TABLE 411 EGYPT: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 303
TABLE 412 EGYPT: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 304
TABLE 413 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 304
TABLE 414 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 305
9.6.4 UAE 305
9.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market 305
TABLE 415 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 305
TABLE 416 UAE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 306
TABLE 417 UAE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 306
TABLE 418 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 307
TABLE 419 UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 307
9.6.5 REST OF MIDDLE EAST & AFRICA 307
TABLE 420 HEMOPHILIA PATIENTS IN REST OF MIDDLE EAST & AFRICA, 2012 VS. 2017 VS. 2018 308
TABLE 421 REST OF MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 308
TABLE 422 REST OF MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021–2028 (USD MILLION) 309
TABLE 423 REST OF MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021–2028 (USD MILLION) 309
TABLE 424 REST OF MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 310
TABLE 425 REST OF MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2021–2028 (USD MILLION) 310
10 COMPETITIVE LANDSCAPE 311
10.1 OVERVIEW 311
10.2 KEY PLAYER STRATEGIES ADOPTED BY MAJOR PLAYERS 311
FIGURE 34 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN PLASMA FRACTIONATION MARKET, 2020–2023 312
10.3 MARKET SHARE ANALYSIS 313
FIGURE 35 PLASMA FRACTIONATION MARKET: MARKET SHARE ANALYSIS, 2022 (TOP 5 PLAYERS) 313
TABLE 426 PLASMA FRACTIONATION MARKET: DEGREE OF COMPETITION 313
10.4 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PLASMA FRACTIONATION MARKET 316
FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN PLASMA FRACTIONATION MARKET (TOP 5) 316
10.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS IN PLASMA FRACTIONATION MARKET 316
10.5.1 STARS 317
10.5.2 EMERGING LEADERS 317
10.5.3 PERVASIVE PLAYERS 317
10.5.4 PARTICIPANTS 317
FIGURE 37 COMPANY EVALUATION MATRIX FOR KEY PLAYERS IN PLASMA FRACTIONATION MARKET, 2022 318
10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 319
TABLE 427 END USER FOOTPRINT ANALYSIS (KEY PLAYERS) 319
TABLE 428 PRODUCT FOOTPRINT ANALYSIS (KEY PLAYERS) 320
TABLE 429 REGIONAL FOOTPRINT ANALYSIS (KEY PLAYERS) 321
10.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES IN PLASMA FRACTIONATION MARKET 322
10.7.1 PROGRESSIVE COMPANIES 322
10.7.2 STARTING BLOCKS 322
10.7.3 RESPONSIVE COMPANIES 322
10.7.4 DYNAMIC COMPANIES 322
FIGURE 38 COMPANY EVALUATION MATRIX FOR START-UPS/SMES IN PLASMA FRACTIONATION MARKET, 2022 323
10.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 324
TABLE 430 DETAILED LIST OF KEY START-UPS/SMES: PLASMA FRACTIONATION MARKET 324
TABLE 431 COMPETITIVE BENCHMARKING OF START-UPS/SMES: PLASMA FRACTIONATION MARKET 325
10.9 COMPETITIVE SCENARIOS AND TRENDS 326
TABLE 432 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2023 326
TABLE 433 KEY DEALS, JANUARY 2021–JULY 2023 327
TABLE 434 OTHER KEY DEVELOPMENTS, JANUARY 2021–JULY 2023 328
11 COMPANY PROFILES 329
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS 329
11.1.1 CSL 329
TABLE 435 CSL: COMPANY OVERVIEW 329
FIGURE 39 CSL: COMPANY SNAPSHOT (2022) 330
11.1.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 335
TABLE 436 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 335
FIGURE 40 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 336
11.1.3 GRIFOLS, S.A. 339
TABLE 437 GRIFOLS, S.A.: COMPANY OVERVIEW 339
FIGURE 41 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022) 340
11.1.4 OCTAPHARMA AG 345
TABLE 438 OCTAPHARMA AG: COMPANY OVERVIEW 345
FIGURE 42 OCTAPHARMA AG: COMPANY SNAPSHOT (2022) 345
11.1.5 KEDRION S.P.A 348
TABLE 439 KEDRION S.P.A: COMPANY OVERVIEW 348
FIGURE 43 KEDRION S.P.A: COMPANY SNAPSHOT (2022) 349
11.1.6 LFB 352
TABLE 440 LFB: COMPANY OVERVIEW 352
11.1.7 ADMA BIOLOGICS, INC. 355
TABLE 441 ADMA BIOLOGICS, INC.: COMPANY OVERVIEW 355
FIGURE 44 ADMA BIOLOGICS, INC.: COMPANY SNAPSHOT (2022) 355
11.1.8 SANQUIN 357
TABLE 442 SANQUIN: COMPANY OVERVIEW 357
FIGURE 45 SANQUIN: COMPANY SNAPSHOT (2022) 357
11.1.9 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. 359
TABLE 443 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: COMPANY OVERVIEW 359
11.1.10 GC PHARMA 361
TABLE 444 GC PHARMA: COMPANY OVERVIEW 361
FIGURE 46 GC PHARMA: COMPANY SNAPSHOT (2021) 361
11.1.11 HUALAN BIOENGINEERING CO., LTD. 363
TABLE 445 HUALAN BIOENGINEERING CO., LTD.: COMPANY OVERVIEW 363
11.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION 365
TABLE 446 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY OVERVIEW 365
11.1.13 EMERGENT 368
TABLE 447 EMERGENT: COMPANY OVERVIEW 368
FIGURE 47 EMERGENT: COMPANY SNAPSHOT (2022) 369
11.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. 371
TABLE 448 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY OVERVIEW 371
11.1.15 INTAS PHARMACEUTICALS LTD. 374
TABLE 449 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW 374
11.2 OTHER PLAYERS 376
11.2.1 BHARAT SERUMS AND VACCINES LIMITED 376
11.2.2 SK PLASMA 377
11.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD. 378
11.2.4 KAMADA PHARMACEUTICALS 379
11.2.5 CENTURION PHARMA 380
11.2.6 PROTHYA BIOSOLUTIONS B.V. 381
11.2.7 PLASMAGEN BIOSCIENCES PVT. LTD. 382
11.2.8 VIRCHOW BIOTECH 382
11.2.9 FUSION HEALTHCARE 383
11.2.10 HEMARUS 384
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 385
12.1 DISCUSSION GUIDE 385
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 389
12.3 CUSTOMIZATION OPTIONS 391
12.4 RELATED REPORTS 391
12.5 AUTHOR DETAILS 392